# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Morgan Stanley analyst Erin Wright maintains CVS Health (NYSE:CVS) with a Overweight and raises the price target from $82 to...
Goldman Sachs analyst Scott Fidel initiates coverage on CVS Health (NYSE:CVS) with a Buy rating and announces Price Target ...
The stock market stumbled Friday after President Donald Trump threatened a sweeping increase in tariffs on Chinese imports, sen...
Confluent explores a sale, Rothschild exits The Economist, Helsing buys Blue Ocean, Zimmer expands robotics, and Omnicare files...
Mizuho analyst Ann Hynes maintains CVS Health (NYSE:CVS) with a Outperform and raises the price target from $76 to $88.
Wells Fargo analyst Stephen Baxter maintains CVS Health (NYSE:CVS) with a Overweight and raises the price target from $84 to...
Pfizer's deal with TrumpRx for steep drug discounts could impact UnitedHealth, Eli Lilly, and CVS. Here's how...